About this Research Topic
The field of breast cancer research has been significantly impacted by the use of immunohistochemical staining as a diagnostic method for determining hormone receptor-positive status. However, the expression rate of these hormone receptors, which is a crucial predictor of endocrine therapy efficacy and a prognostic factor, is still a subject of ongoing debate. The current ASCO/CAP guidelines recommend a 1% nuclear staining cutoff, but a definitive consensus on this value has not been reached. Furthermore, the treatment strategy for hormone receptor-low expression breast cancer lacks clear criteria, leading to challenges in determining the appropriateness of CDK4/6 inhibitors and chemotherapy as adjuvant therapies.
This research topic aims to delve into the complexities of hormone receptor-low expression breast cancer, an emerging and significant subtype. The main objective is to illuminate the fundamental characteristics and clinical aspects of this subtype in greater detail. By exploring the unique properties and pathological elements associated with this subtype, we hope to share the latest research findings and clinical data to enhance understanding. The ultimate goal is to uncover new insights that could prove beneficial in the realms of treatment strategies and prognosis assessment.
To gather further insights into the management of hormone receptor-low expression breast cancer, we welcome articles addressing, but not limited to, the following themes:
- The role of immunohistochemical staining in diagnosing hormone receptor-positive status
- The impact of hormone receptor expression rate on endocrine therapy efficacy
- The ongoing debate regarding the ASCO/CAP guidelines' recommended nuclear staining cutoff
- The challenges in determining the appropriateness of CDK4/6 inhibitors and chemotherapy as adjuvant therapies for hormone receptor-low expression breast cancer
- The unique properties and pathological elements associated with hormone receptor-low expression breast cancer.
This research topic aims to delve into the complexities of hormone receptor-low expression breast cancer, an emerging and significant subtype. The main objective is to illuminate the fundamental characteristics and clinical aspects of this subtype in greater detail. By exploring the unique properties and pathological elements associated with this subtype, we hope to share the latest research findings and clinical data to enhance understanding. The ultimate goal is to uncover new insights that could prove beneficial in the realms of treatment strategies and prognosis assessment.
To gather further insights into the management of hormone receptor-low expression breast cancer, we welcome articles addressing, but not limited to, the following themes:
- The role of immunohistochemical staining in diagnosing hormone receptor-positive status
- The impact of hormone receptor expression rate on endocrine therapy efficacy
- The ongoing debate regarding the ASCO/CAP guidelines' recommended nuclear staining cutoff
- The challenges in determining the appropriateness of CDK4/6 inhibitors and chemotherapy as adjuvant therapies for hormone receptor-low expression breast cancer
- The unique properties and pathological elements associated with hormone receptor-low expression breast cancer.
Keywords: Breast Cancer, Estrogen Receptor, Progesterone Receptor Hormone, Management, Treatment Approaches
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
